Experimental and Clinical Aspects of using luteinizing hormone-releasing factor and its analogs

Abstract

This literature review briefly summarizes the methods of application and the conditions necessary from the physiological point of view to activate the secretion of gonadotropins by the pituitary gland by stimulating the luteinizing hormone-releasing hormone (LH-RH) in a pulsating mode, and we compare the effect of the pituitary stimulating LH-RH- agonists. The structure of LT-RG was explained in 1971 by Matsuo, Baba, in 1972 by F. Burgus, J. Butcher and confirmed in 1971 by the synthesis of Geiger, Konigi Wissmann. Studies conducted over 10 years showed that LG-RG , as well as its analogs are important for clinical practice. There are 2 active groups of agonist analogs. The 1st includes LH-RH analogs with an altered amino acid sequence and is abbreviated Trp "LH-RH. These peptides have a structure very similar to the natural LH-RH. The 2nd group combines LH-RH of 1-9-nano-peptidethylamide agonists. These peptides differ from LH-RG in their C-terminal sequence, Pro9-ethylamide, Leu6 is introduced - LH-RH (l-9-ethylamide), which is abbreviated as Leu6-EA- (1-Trp6), LH-RH (1-9 -ethylamide) - abbreviated as Trp-EA-Z-Ser (Bu +) 6, LH-RH 1-9-ethylamide - l-Ser- (Bu +) 6-EA.